Publications by authors named "Silas Martin"

Claim this Profile
I
Income, health, and racial gaps between 340B hospitals, child sites, and nearby neighborhoods.
Neal Masia, Darren Filson, Silas Martin, Ulrich Neumann

Health Aff Sch· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Public sector replacement of privately funded pharmaceutical R&D: cost and efficiency considerations.
David Proudman, Urvi Desai, Dumingu Aparna Gomes, Maks Khomenko, Silas Martin

J Med Econ· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive measurement of biopharmaceutical R&D investment.
Amitabh Chandra, John Drum, Michael Daly, Henry Mirsberger, Samuel Spare, Silas Martin

Nat Rev Drug Discov· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Authors' Reply to the Letter to the Editor by Liu and Kesselheim.
Bridget Doherty, Silas Martin, Ágnes Benedict

J Natl Compr Canc Netw· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bis[2-(isoquinolin-1-yl)phenyl-κ , ](2-phenyl-1-imidazo[4,5-][1,10]phenanthroline-κ ,')iridium(III) hexa-fluorido-phosphate methanol monosolvate.
Silas Martin, William W Brennessel, Ammar Hasan, Carly R Reed

IUCrdata· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio Model.
Ágnes Benedict, Gábor Szabó, Kinga Marczell, Bridget Doherty, Silas Martin

J Natl Compr Canc Netw· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
Ari D Panzer, Michael Ingham, Silas Martin, James D Chambers

J Manag Care Spec Pharm· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of non-medical switching among ambulatory patients: an updated systematic literature review.
Erin R Weeda, Elaine Nguyen, Silas Martin, Michael Ingham, Diana M Sobieraj

J Mark Access Health Policy· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CMS hospital readmission reduction program and anticoagulants received following a total hip and knee arthroplasty discharge.
François Laliberté, Craig I Coleman, Brahim Bookhart, Jeff Schein, Silas Martin

Curr Med Res Opin· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation.
Scott Kaatz, Craig I Coleman, Brahim Bookhart, François Laliberté, Winnie W Nelson, Silas Martin

Curr Med Res Opin· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications.
Concetta Crivera, Winnie W Nelson, Brahim Bookhart, Silas Martin, Guillaume Germain

Curr Med Res Opin· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure.
Colleen A McHorney, Concetta Crivera, François Laliberté, Winnie W Nelson, Guillaume Germain, Silas Martin

Curr Med Res Opin· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control.
Marie-Hélène Lafeuille, Amanda Melina Grittner, Jonathan Gravel, Robert A Bailey, Silas Martin

J Med Econ· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost efficiency of canagliflozin versus sitagliptin for type 2 diabetes mellitus.
Varun U Ektare, Janice M S Lopez, Silas C Martin, Dipen A Patel, Marcia F T Rupnow

Am J Manag Care· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012).
Alex Ward, Piedad Alvarez, Lien Vo, Silas Martin

J Med Econ· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.
Robert A Bailey, C V Damaraju, Silas C Martin, Gary E Meininger, Marcia F T Rupnow

Am J Manag Care· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality measure attainment in patients with type 2 diabetes mellitus.
Marie-Hélène Lafeuille, Amanda M Grittner, Jonathan Gravel, Robert A Bailey, Silas Martin

Am J Manag Care· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection.
Josephine Mauskopf, Anita J Brogan, Sandra E Talbird, Silas Martin

AIDS· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The value to patients of reducing lesion severity in plaque psoriasis.
A Brett Hauber, Juan Marcos Gonzalez, Brad Schenkel, Jennifer H Lofland, Silas Martin

J Dermatolog Treat· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis.
Silas Martin, Steven R Feldman, Matthias Augustin, Philippe Szapary, Brad Schenkel

J Dermatolog Treat· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.
Josephine Mauskopf, Anita Brogan, Silas Martin, Erik Smets

Pharmacoeconomics· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometric evaluation of the functional assessment of HIV Infection (FAHI) questionnaire and its usefulness in clinical trials.
Muriel Viala-Danten, Dominique Dubois, Hélène Gilet, Silas Martin, Katrien Peeters

Qual Life Res· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacoeconomics of etravirine.
D S Fullerton, Mary Jane Watson, David Anderson, James Witek, Silas C Martin

Expert Rev Pharmacoecon Outcomes Res· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of etravirine versus placebo on health-related quality of life in treatment-experienced HIV patients as measured by the functional assessment of human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials.
David Cella, Hélène Gilet, Muriel Viala-Danten, Katrien Peeters, Dominique Dubois, Silas Martin

HIV Clin Trials· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-based utilities for bipolar disorder-related health states.
Dennis A Revicki, Jennifer Hanlon, Silas Martin, Laszlo Gyulai, S Nassir Ghaemi

J Affect Disord· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis